The UK’s National Institute for Health and Care Excellence (NICE) has approved Novartis’ drug Kisqali (ribociclib) in combination with fulvestrant...
Read More...
The post UK’s NICE backs Novartis breast cancer drug Kisqali appeared first on Pharmaceutical Technology.
Original Article: UK’s NICE backs Novartis breast cancer drug Kisqali